search
Back to results

Automated Variable Pattern Insufflator Device (AVPI) for the Acute Treatment of Migraine

Primary Purpose

Migraine Headache

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Automated Variable Pressure Insufflation
Sponsored by
Nocira, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Migraine Headache

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. At least 18 years of age at the time of the baseline visit.
  2. Episodic migraine with or without aura diagnosed according to the International Classification of Headache Disorders 3 beta diagnostic criteria.
  3. Migraine onset before the age of 50 years
  4. Migraine present for at least 1 year at the time of the Baseline Visit.
  5. Frequency of 1-12 migraine attacks per month in each of the 2 months prior to screening.
  6. Willingness, ability, and commitment to participate in baseline and follow-up evaluations without concurrent participation in another clinical trial.
  7. Signed patient informed consent form.

Exclusion Criteria:

  1. Prior or current diagnosis of migraine with brainstem aura, hemiplegic migraine, retinal migraine, migraine aura without headache, vestibular migraine.
  2. Use of acute headache medication within previous 48 hours of treatment visit (for each treatment visit).
  3. Use of acute medication for headache on >15 days per month in the 3 months prior to the Baseline Visit.
  4. Change in migraine preventive therapies or dosage within the preceding 1 month of Baseline Visit.
  5. Use of an opioid or barbiturate on more than 4 days per month in each of the 3 months prior to the Baseline Visit.
  6. Other primary headache disorder, other than tension-type headache on 3 or fewer days per month.
  7. History of secondary non-migraine headache disorders.
  8. Medical history of Meniere's disease; endolymphatic hydrops; loss of hearing in either ear that is either complete, requires a hearing aid, or has deteriorated noticeably over the past year; ear surgery (including ear tubes); chronic continuous or current tinnitus; superior canal dehiscence.
  9. Discomfort, infection, or other abnormal symptoms or disorders of either ear within 1 month prior to the enrollment Screening or Treatment Visit.
  10. Pregnant or trying to become pregnant.
  11. Unable to provide informed consent.
  12. Inability to present to the medical clinic for study treatment during a migraine attack.
  13. Unable or unlikely to follow instructions for proper use of the device.
  14. Presence of any condition or state that would prevent the subject from sitting or lying down during the course of the treatment (up to 30 minutes).
  15. History of receiving ear pressure therapy (insufflation) to treat any condition.
  16. Personal or family affiliation as a service provider (e.g. employee, contractor, consultant, or volunteer) with a migraine treatment device company other than the study sponsor.
  17. Perforated or compromised tympanic membrane, and which is confirmed by otoscope inspection by the Investigator before or upon presentation of the subject for the Treatment Visit.
  18. Any other information about the subject's medical condition that, in the reasonable professional judgement of the Investigator, may adversely affect the intended safety or results of the treatment as intended and as a reasonable basis to exclude the subject.

Sites / Locations

  • Regen Pain and Wellness
  • Murray Chiropractic Neurology
  • StudyMetrix

Arms of the Study

Arm 1

Arm 2

Arm Type

Sham Comparator

Experimental

Arm Label

Sham treatment

Active Treatment

Arm Description

The AVPI device software is set in "sham mode" which does not deliver the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used.

The AVPI device software is set in "active mode" which delivers the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used.

Outcomes

Primary Outcome Measures

Pain Freedom Rates - active
Pain freedom rates (PFR)

Secondary Outcome Measures

Full Information

First Posted
October 6, 2020
Last Updated
September 8, 2022
Sponsor
Nocira, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT04584762
Brief Title
Automated Variable Pattern Insufflator Device (AVPI) for the Acute Treatment of Migraine
Official Title
Automated Variable Pattern Insufflator Device (AVPI) for the Acute Treatment of Migraine: a Prospective, Randomized, Double-blind, Parallel Group, Sham-controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 9, 2020 (Actual)
Primary Completion Date
June 30, 2022 (Actual)
Study Completion Date
October 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nocira, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Randomized, sham-controlled, double-blind study for acute migraine attacks. Randomized to active treatment and sham treatment arms for the first treatment. Optional second active treatment. Follow up at 0, 2 and 24 hours post-treatment.
Detailed Description
Randomized, sham-controlled, double-blind study for acute migraine attacks. Treatment Phase: • ≤60 days to present at clinic for treating up to 2 migraines (at least 48 hours apart). First treatment is randomized between active treatment and sham treatment. Second optional treatment is open-label. Post-Treatment Follow-up Phase: 24 hours after initiating treatment, for each of up to two migraine treatments, for conducting post-treatment follow-up assessments of migraine symptoms. 30, 60, and 90 days following the first migraine treatment for migraine diary assessments (and MIDAS assessment at 90 days) Collection of migraine diaries at 30, 60, & 90 days post enrollment. Collection of MIDAS data at 60 and 90 days post treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine Headache

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective, randomized, double-blind, parallel group, sham-controlled
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sham treatment
Arm Type
Sham Comparator
Arm Description
The AVPI device software is set in "sham mode" which does not deliver the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used.
Arm Title
Active Treatment
Arm Type
Experimental
Arm Description
The AVPI device software is set in "active mode" which delivers the therapy to the subject. Neither the subject or the investigator is aware of which mode is being used.
Intervention Type
Device
Intervention Name(s)
Automated Variable Pressure Insufflation
Intervention Description
Acute migraine treatment
Primary Outcome Measure Information:
Title
Pain Freedom Rates - active
Description
Pain freedom rates (PFR)
Time Frame
2 Hours post treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: At least 18 years of age at the time of the baseline visit. Episodic migraine with or without aura diagnosed according to the International Classification of Headache Disorders 3 beta diagnostic criteria. Migraine onset before the age of 50 years Migraine present for at least 1 year at the time of the Baseline Visit. Frequency of 1-12 migraine attacks per month in each of the 2 months prior to screening. Willingness, ability, and commitment to participate in baseline and follow-up evaluations without concurrent participation in another clinical trial. Signed patient informed consent form. Exclusion Criteria: Prior or current diagnosis of migraine with brainstem aura, hemiplegic migraine, retinal migraine, migraine aura without headache, vestibular migraine. Use of acute headache medication within previous 48 hours of treatment visit (for each treatment visit). Use of acute medication for headache on >15 days per month in the 3 months prior to the Baseline Visit. Change in migraine preventive therapies or dosage within the preceding 1 month of Baseline Visit. Use of an opioid or barbiturate on more than 4 days per month in each of the 3 months prior to the Baseline Visit. Other primary headache disorder, other than tension-type headache on 3 or fewer days per month. History of secondary non-migraine headache disorders. Medical history of Meniere's disease; endolymphatic hydrops; loss of hearing in either ear that is either complete, requires a hearing aid, or has deteriorated noticeably over the past year; ear surgery (including ear tubes); chronic continuous or current tinnitus; superior canal dehiscence. Discomfort, infection, or other abnormal symptoms or disorders of either ear within 1 month prior to the enrollment Screening or Treatment Visit. Pregnant or trying to become pregnant. Unable to provide informed consent. Inability to present to the medical clinic for study treatment during a migraine attack. Unable or unlikely to follow instructions for proper use of the device. Presence of any condition or state that would prevent the subject from sitting or lying down during the course of the treatment (up to 30 minutes). History of receiving ear pressure therapy (insufflation) to treat any condition. Personal or family affiliation as a service provider (e.g. employee, contractor, consultant, or volunteer) with a migraine treatment device company other than the study sponsor. Perforated or compromised tympanic membrane, and which is confirmed by otoscope inspection by the Investigator before or upon presentation of the subject for the Treatment Visit. Any other information about the subject's medical condition that, in the reasonable professional judgement of the Investigator, may adversely affect the intended safety or results of the treatment as intended and as a reasonable basis to exclude the subject.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David George
Organizational Affiliation
Nocira, LLC
Official's Role
Study Director
Facility Information:
Facility Name
Regen Pain and Wellness
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85254
Country
United States
Facility Name
Murray Chiropractic Neurology
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33701
Country
United States
Facility Name
StudyMetrix
City
Saint Charles
State/Province
Missouri
ZIP/Postal Code
63303
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Automated Variable Pattern Insufflator Device (AVPI) for the Acute Treatment of Migraine

We'll reach out to this number within 24 hrs